Filing Details
- Accession Number:
- 0001209191-22-041440
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-07-07 16:04:11
- Reporting Period:
- 2022-07-06
- Accepted Time:
- 2022-07-07 16:04:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1748177 | Bahram Valamehr | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | Chief R&D Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-07-06 | 2,000 | $4.84 | 181,834 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2022-07-06 | 5,842 | $2.73 | 187,676 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-07-06 | 7,842 | $30.07 | 179,834 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-07-06 | 2,000 | $4.84 | 2,000 | $4.84 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-07-06 | 5,842 | $2.73 | 5,842 | $2.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 8,704 | 2025-01-05 | No | 4 | M | Direct | |
| 30,314 | 2027-01-04 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2020.
- Represents the weighted average sale price of the shares sold ranging from $30.00 to $30.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range set forth in footnote 2.
- This option is fully vested.
Billionaire Hedge Funds
